EFTA00304997.pdf

Report Status: Final 410) Quest Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Chentheonnation Specimen: MR156329E Client #: 78300020 56W5265 EPSTEIN, JEFFREY Requisition: 0004002 MOSKOWITZ. BRUCE W DOB: 01/20/1953 AGE: 64 BRUCE MOSKOWITZ, MD Gender: M Attn: NATIONWIDE ACCOUNT Collected: 01/05/2018 Phone: 1411 N FLAGLER DR STE 7100 Received: 01/05/2018 122:36 EST Patient ID: 19530120MJE WEST PALM BEACH, FL 33401-3418 Reported: 01/08/2018 123:26 EST Health ID: 8573003290851249 Teat Name In Range Out Of Range Reference Range Lab LIPID PANEL CHOLESTEROL, TOTAL 207 H <200 mg/dL MI HDL CHOLESTEROL 28 L >40 mg/dL MI TRIGLYCERIDES 510 H <150 mg/dL MI LDL-CHOLESTEROL mg/dL (talc) MI LDL cholesterol not calculated. Triglyceride levels greater than 400 mg/dL invalidate calculated LDL results. Reference range: <100 Desirable range <100 mg/dL for patients with CHD or diabetes and <70 mg/dL for diabetic patients with known heart disease. LDL-C is now calculated using the Martin-Hopkins calculation, which is a validated novel method providing better accuracy than the Friedewald equation in the estimation of LDL-C. Martin SS et al. JAMA. 2013;310(19): 2061-2068 (http://education.QuestDiagnostics.com/faq/FAQ164) CHOL/HDLC RATIO 7.4 H <5.0 (talc) MI NON HDL CHOLESTEROL 179 H <130 mg/dL (talc) MI For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option. HS CRP 1.2 mg/L TP Average relative cardiovascular risk according to AHA/CDC guidelines. For ages >17 Years: hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk. 1.0-3.0 Average relative cardiovascular risk. 3.1-10.0 Higher relative cardiovascular risk. Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation. >10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation. HOMOCYSTEINE 13.7 H <11.4 umol/L MI Homocysteine is increased by functional deficiency of folate or vitamin B12. Testing for methylmalonic acid differentiates between these deficiencies. Other causes of increased homocysteine include renal failure, folate antagonists such as methotrexate and phenytoin, and exposure to nitrous oxide. CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E PAGE I OF 5 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00304997  Report Status: Final 60) —.• Quest Diagnostics' EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR156329E Client #: 78300020 EPSTEIN, JEFFREY Collected: 01/05/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Reported: 01/08/2018 /23:26 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab COMPREHENSIVE METABOLIC MI PANEL GLUCOSE 90 65-99 mg/dL Fasting reference interval UREA NITROGEN (BUN) 20 7-25 mg/dL CREATININE 1.10 0.70-1.25 mg/dL For patients >49 years of age, the reference limit for Creatinine is approximately 13% higher for people identified as African-American. eGFR NON-AFR. AMERICAN 71 > OR = 60 mL/min/1.73m2 eGFR AFRICAN AMERICAN 82 > OR = 60 mL/min/1.73m2 BUN/CREATININE RATIO NOT APPLICABLE 6-22 (talc) SODIUM 147 H 135-146 mmol/L POTASSIUM 4.7 3.5-5.3 mmol/L CHLORIDE 112 H 98-110 mmol/L CARBON DIOXIDE 23 20-31 mmol/L CALCIUM 9.8 8.6-10.3 mg/dL PROTEIN, TOTAL 7.3 6.1-8.1 g/dL ALBUMIN 4.3 3.6-5.1 g/dL GLOBULIN 3.0 1.9-3.7 g/dL (talc) ALBUMIN/GLOBULIN RATIO 1.4 1.0-2.5 (talc) BILIRUBIN, TOTAL 0.8 0.2-1.2 mg/dL ALKALINE PHOSPHATASE 56 40-115 U/L AST 22 10-35 U/L ALT 26 9-46 U/L HEMOGLOBIN Alc 5.5 <5.7 % of total Hgb MI For the purpose of screening for the presence of diabetes: <5.7% Consistent with the absence of diabetes 5.7-6.4% Consistent with increased risk for diabetes (prediabetes) > or =6.5% Consistent with diabetes This assay result is consistent with a decreased risk of diabetes. Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children. According to American Diabetes Association (ADA) guidelines, hemoglobin Alc <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA). URIC ACID 8.0 4.0-8.0 mg/dL MI Therapeutic target for gout patients: <6.0 mg/dL TSH 3.05 0.40-4.50 mIU/L MI T4 (THYROXINE), TOTAL 7.8 4.5-12.0 mcg/dL MI FREE T4 INDEX (T7) 2.1 1.4-3.8 T3 UPTAKE 27 22-35 % MI CLIENT SERVICES: 866.697.8378 SPECIMEN: MRI56329E PAGE 2 OF 5 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00304998  Report Status: Final 61 1) Quest —00 Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Clientheonnation Specimen: MR156329E Client #: 78300020 EPSTEIN, JEFFREY Collected: 01/05/2018 MOSKOWITZ,BRUCE W DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 /22:36 EST Gender: M Reported: 01/08/2018 /23:26 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab SED RATE BY MODIFIED MI WESTERGREN 9 < OR = 20 mm/h CBC (INCLUDES DIFF/PLT) MI WHITE BLOOD CELL COUNT 6.2 3.8-10.8 Thousand/uL RED BLOOD CELL COUNT 5.17 4.20-5.80 Million/uL HEMOGLOBIN 14.9 13.2-17.1 g/dL HEMATOCRIT 43.8 38.5-50.0 % MCV 84.7 80.0-100.0 fL MCH 28.8 27.0-33.0 pg MCHC 34.0 32.0-36.0 g/dL RDW 13.7 11.0-15.0 % PLATELET COUNT 265 140-400 Thousand/uL MPV 10.3 7.5-12.5 fL ABSOLUTE NEUTROPHILS 2895 1500-7800 cells/uL ABSOLUTE LYMPHOCYTES 2331 850-3900 cells/uL ABSOLUTE MONOCYTES 515 200-950 cells/uL ABSOLUTE EOSINOPHILS 391 15-500 cells/uL ABSOLUTE BASOPHILS 68 0-200 cells/uL NEUTROPHILS 46.7 LYMPHOCYTES 37.6 MONOCYTES 8.3 EOSINOPHILS 6.3 BASOPHILS 1.1 URINALYSIS, COMPLETE MI COLOR YELLOW YELLOW APPEARANCE CLEAR CLEAR SPECIFIC GRAVITY 1.023 1.001-1.035 PH < OR = 5.0 5.0-8.0 GLUCOSE NEGATIVE NEGATIVE BILIRUBIN NEGATIVE NEGATIVE KETONES NEGATIVE NEGATIVE OCCULT BLOOD NEGATIVE NEGATIVE PROTEIN NEGATIVE NEGATIVE NITRITE NEGATIVE NEGATIVE LEUKOCYTE ESTERASE NEGATIVE NEGATIVE WBC NONE SEEN < OR = 5 /HPF RBC 0-2 < OR = 2 /HPF SQUAMOUS EPITHELIAL CELLS NONE SEEN < OR = 5 /HPF BACTERIA NONE SEEN NONE SEEN /HPF HYALINE CAST NONE SEEN NONE SEEN /LPF VITAMIN B12 471 200-1100 pg/mL MI C-REACTIVE PROTEIN 1.4 <8.0 mg/L MI MERCURY, BLOOD <5 <OR=10 mcg/L AT This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. TESTOSTERONE, TOTAL MI MALES (ADULT), IA TESTOSTERONE, TOTAL, MALES (ADULT), IA 150 L 250-827 ng/dL In hypogonadal males, Testosterone, Total, LC/MS/MS, is the recommended assay due to the diminished accuracy of immunoassay at levels below 250 ng/dL. CLIENT SERVICES:866.697.8378 SPECIMEN: MR156329E PAGE30F5 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00304999  Report Status: Final raj —.0 Quest Diagnostics' EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR156329E Client #: 78300020 EPSTEIN, JEFFREY Collected: 01/05/2018 MOSKOWITZ, BRUCE W DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Reported: 01/08/2018 / 23:26 EST Patient ID: 19530120MJE Health ID: 8573003290851249 Test Name In Range Out Of Range Reference Range Lab This test code (15983) must be collected in a red-top tube with no gel. PSA, TOTAL 0.5 < OR = 4.0 ng/mL MI The total PSA value from this assay system is standardized against the WHO standard. The test result will be approximately 20% lower when compared to the equimolar-standardized total PSA (Beckman Coulter). Comparison of serial PSA results should be interpreted with this fact in mind. This test was performed using the Siemens chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. PSA levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease. CLIENTSERIIICES:866.6971378 SPECIMEN: MR156329E PAGE 4 OF 5 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00305000  Report Status: Final Quest Diagnostics EPSTEIN, JEFFREY Patient Information Specimen Information Client Information Specimen: MR156329E Client #: 78300020 EPSTEIN, JEFFREY Collected: 01/05/2018 MOSKOWITZ. BRUCE W DOB: 01/20/1953 AGE: 64 Received: 01/05/2018 / 22:36 EST Gender: M Reported: 01/08/2018 / 23:26 EST Patient ID: 19530120NUE Health ID: 8573003290851249 Endocrinology Test Name Result Reference Range Lab VITAMIN D,25-OH,TOTAL,IA 35 30-100 ng/mL MI Vitamin D Status 25-OH Vitamin D: Deficiency: <20 ng/mL Insufficiency: 20 - 29 ng/mL Optimal: > or = 30 ng/mL For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the OuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs). For more information on this test, go to: http:fieducation.questdiagnostics.com/faq/FAC1163 (This link is being provided for informational/ educational purposes only.) Physician Comments: PERFORMING SITE: AT QUEST DIAGNOSTICS.A1LANTA. 1777 MONTREAL CIRCLE.11JCICER. GA 30084-6S02 laboratory Dutch:. ANDREW N YOUNG.MD.PIID.CLIA: 1100255931 MI QUEST DIAGNOSTICS.MIAMI 10200 COMMERCE PARKWAY. MIRAMAR. Fl. 33015-3938 Laboratory Director GLEN L 11OR11N MD PHD. CLIA: 10/1027731/ TP QUEST DIAGNOSTICS.TAMPA. 1223 E FOWLER AVE TAMPA. It 33617.2026 Laboratory Director. GLEN L HORTIN.MDAID. CL1A: 10110291120 CLIENT SERVICES: 866.697.8378 SPECIMEN: MR156329E PAGE 5 OF 5 Quest. Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the trademarks of Quest Diagnostics. EFTA00305001